OP018/#414 Progression free survival and overall survival after BRCA1/2-ASSOCIATED epithelial ovarian cancer: a matched cohort study

Autor: Bernadette A. M. Heemskerk-Gerritsen, W.J. van Driel, Marian J.E. Mourits, Maartje J. Hooning, E Gómez Garcia, IA Boere, I Van Den Beek, A Hollestelle, M Koudijs, J.A. de Hullu, K Van Engelen

Publikováno v: Oral Featured Posters.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb1b47a82b62135fc7812f0114555c97
https://doi.org/10.1136/ijgc-2021-igcs.35

280 Improvement of complete cytoreduction for advanced-stage ovarian cancer with adjuvant use of the PlasmaJet Device. Results of a RCT

Autor: G Nieuwenhuyzen-de Boer, S Willemsen, HJ Van Beekhuizen, PC Ewing-Graham, Astrid Baalbergen, IG Schoots, IA Boere, AMLDVan Haaften-de Jong, N. Reesink-Peters, I Nedelcu, J.J. Beltman, L. Hofman, Hmj Werner, L. Haans, M. Dorman, W. Hofhuis, W.J. van Driel, J Piek

Publikováno v: Ovarian cancer.

Results of the PlaComOv-study, a randomized, controlled trial in the Netherlands Introduction/Background* The most important prognostic factor for patients with advanced-stage ovarian cancer is complete cytoreductive surgery (CRS). Standard surgical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e5771cc22ca21b9488cfe2f65f8664e
https://doi.org/10.1136/ijgc-2021-esgo.375

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

Autor: Stroot IAS; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands. Electronic address: i.a.s.stroot@umcg.nl., Bart J; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Hollema H; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Jalving M; University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands., Wagner MM; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., Yigit R; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., van Doorn HC; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Gynecologic Oncology, Rotterdam, the Netherlands., de Hullu JA; Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Gaarenstroom KN; Leiden University Medical Center, Department of Obstetrics and Gynecology, Leiden, the Netherlands., van Beurden M; Antoni van Leeuwenhoek, Department of Gynecology, Amsterdam, the Netherlands., van Lonkhuijzen LRCW; Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Department of Gynecologic Oncology, Amsterdam, the Netherlands., Slangen BFM; Maastricht University Medical Center, Department of Gynecology, Maastricht, the Netherlands., Zweemer RP; University Medical Center Utrecht, Department of Gynecologic Oncology, Utrecht, the Netherlands., Gómez García EB; University Medical Center Maastricht, Department of Clinical Genetics, Maastricht, the Netherlands., Ausems MGEM; University Medical Center Utrecht, Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, Utrecht, the Netherlands., Boere IA; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Medical Oncology, Rotterdam, the Netherlands., van Hest LP; Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., Duijkers FAM; Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., van Asperen CJ; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Schmidt MK; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands; Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, the Netherlands; Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, the Netherlands., Wevers MR; Radboud University Medical Center, Department of Clinical Genetics, Nijmegen, the Netherlands., Ruijs MWG; Netherlands Cancer Institute, Department of Clinical Genetics, Amsterdam, the Netherlands., Devilee P; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Collée JM; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, the Netherlands., Hebon Investigators; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, the Netherlands., de Bock GH; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands., Mourits MJE; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Aug; Vol. 187, pp. 198-203. Date of Electronic Publication: 2024 May 24.

Tropomyosin1 isoforms underlie epithelial to mesenchymal plasticity, metastatic dissemination, and resistance to chemotherapy in high-grade serous ovarian cancer.

Autor: Xu T; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Verhagen MP; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Teeuwssen M; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.; Elisabeth-TweeSteden Ziekenhuis (ETZ), Tilburg, The Netherlands., Sun W; Institut Curie, Laboratory of Genetics and Developmental Biology, Paris, France., Joosten R; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Sacchetti A; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Ewing-Graham PC; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Jansen MPHM; Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands., Boere IA; Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands., Bryce NS; School of Biomedical Sciences, Faculty of Medicine and Health, The University of New South Wales, Sydney, New South Wales, Australia.; The Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia., Zeng J; Computist Bio-NanoTech, Scoresby, VIC, 3179, Australia., Treutlein HR; Computist Bio-NanoTech, Scoresby, VIC, 3179, Australia.; Sanoosa Pty. Ltd, Moonee Ponds, VIC, 3039, Australia., Hook J; School of Biomedical Sciences, Faculty of Medicine and Health, The University of New South Wales, Sydney, New South Wales, Australia., Hardeman EC; School of Biomedical Sciences, Faculty of Medicine and Health, The University of New South Wales, Sydney, New South Wales, Australia., Gunning PW; School of Biomedical Sciences, Faculty of Medicine and Health, The University of New South Wales, Sydney, New South Wales, Australia., Fodde R; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. r.fodde@erasmusmc.nl.

Publikováno v: Cell death and differentiation [Cell Death Differ] 2024 Mar; Vol. 31 (3), pp. 360-377. Date of Electronic Publication: 2024 Feb 16.

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.

Autor: Vergote I; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, Leuven, Belgium., Van Nieuwenhuysen E; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, Leuven, Belgium., O'Cearbhaill RE; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY., Westermann A; Dutch Gynaecological Oncology Group, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Lorusso D; Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Catholic University of Sacred Heart, Rome, Italy., Ghamande S; Department of Obstetrics and Gynecology, Augusta University, Augusta, GA., Collins DC; Department of Medical Oncology, Cancer Trials Ireland, Cork University Hospital, Cork, Ireland., Banerjee S; Royal Marsden National Health Service Foundation Trust, Institute of Cancer Research, London, United Kingdom., Mathews CA; Program in Women's Oncology, Women & Infants Hospital, Legorreta Cancer Center at Alpert Medical School of Brown University, Providence, RI., Gennigens C; BGOG, Centre Hospitalier Universitaire de Liège, Liège, Belgium., Cibula D; Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Tewari KS; University of California, Irvine, CA., Madsen K; Centre for Cancer and Organ Diseases, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark., Köse F; Baskent University, Ankara, Turkey., Jackson AL; Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati, OH., Boere IA; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Scambia G; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Randall LM; School of Medicine, Virginia Commonwealth University, Richmond, VA., Sadozye A; Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, United Kingdom., Baurain JF; Cliniques Universitaires Saint-Luc and Université Catholique de Louvain and BGOG, Brussels, Belgium., Gort E; University Medical Center Utrecht, Utrecht, the Netherlands., Zikán M; First Faculty of Medicine, Bulovka University Hospital, Charles University, Prague, Czech Republic., Denys HG; BGOG, Ghent University Hospital, Ghent, Belgium., Ottevanger N; Radboudumc, Nijmegen, the Netherlands., Forget F; BGOG, Centre Hospitalier de l'Ardenne-Site de Libramont, Libramont-Chevigny, Belgium., Mondrup Andreassen C; Genmab A/S, Copenhagen, Denmark., Eaton L; Genmab US, Princeton, NJ., Chisamore MJ; Merck & Co, Inc, Rahway, NJ., Viana Nicacio L; Seagen, Bothell, WA., Soumaoro I; Genmab US, Princeton, NJ., Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 20; Vol. 41 (36), pp. 5536-5549. Date of Electronic Publication: 2023 Aug 31.